Home Cart Sign in  
Chemical Structure| 1258392-53-8 Chemical Structure| 1258392-53-8

Structure of AZD5582
CAS No.: 1258392-53-8

Chemical Structure| 1258392-53-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AZD5582 is a class of dimeric Smac mimetics as potent IAP antagonist and binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP (IC50 = 15, 21, and 15 nM, respectively).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AZD5582

CAS No. :1258392-53-8
Formula : C58H78N8O8
M.W : 1015.28
SMILES Code : CN[C@@H](C)C(N[C@H](C(N1[C@H](C(N[C@H]2C3=CC=CC=C3C[C@H]2OCC#CC#CCO[C@H]4[C@@H](NC([C@@H]5CCCN5C([C@@H](NC([C@H](C)NC)=O)C6CCCCC6)=O)=O)C(C=CC=C7)=C7C4)=O)CCC1)=O)C8CCCCC8)=O
MDL No. :MFCD28411397
InChI Key :WLMCRYCCYXHPQF-ZVMUOSSASA-N
Pubchem ID :49847690

Safety of AZD5582

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • cIAP

    cIAP2, IC50:21 nM

    cIAP1, IC50:15 nM

  • XIAP

    XIAP, IC50:15 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
A66 cells 33 ng/ml 4 hours To assess viral gene expression in SIVmac239-infected cells Nat Med. 2023 Oct;29(10):2535-2546.
Jurkat cells 5 nM 16 hours To investigate the role of AZD5582 in HIV-1 latency reversal, results showed that AZD5582 induces HIV-1 gene expression by activating the ncNF-κB pathway Sci Transl Med. 2022 Oct 19;14(667):eabh3351.
Breast cancer cell lines 10 nM 2 and 8 hours Evaluate the synergism between AZD5582 and TRAIL, observed highly synergistic activity in ~30% of cell lines Cell Death Dis. 2015 Oct 1;6(10):e1893.
Total CD4+ T cells 100 nM 24 hours To evaluate the effect of AZD5582 on the ncNF-κB pathway, results showed that AZD5582 degrades cIAP1 and activates p100/p52. Nature. 2020 Feb;578(7793):160-165.
Jurkat cells 1-10 nM 24 hours To evaluate the effect of AZD5582 on HIV latency reversal, results showed that AZD5582 significantly reversed HIV latency. iScience. 2021 Dec 18;25(1):103649.
U1 cells 500 nM 24 hours To evaluate the effect of AZD5582 on HIV latency reversal in U1 cells, results showed that high concentration AZD5582 reversed HIV latency. iScience. 2021 Dec 18;25(1):103649.
Jurkat cells 10 pM to 1 µM 48 hours To evaluate the induction of HIV transcription by AZD5582, results showed that AZD5582 effectively induces HIV transcription. Nature. 2020 Feb;578(7793):160-165.
Primary CD4+ T cells 100 nM 48 hours To evaluate the effect of AZD5582 on HIV latency reversal in primary CD4+ T cells, results showed that AZD5582 reversed HIV latency. iScience. 2021 Dec 18;25(1):103649.
H1975 human NSCLC cell line 20 nM 48 hours AZD5582 alone slightly inhibited cell viability, but it could cooperate with IFNγ to profoundly induce cell death Cancer Cell Int. 2018 Jun 14;18:84.
HCC827 human NSCLC cell line 20 nM 48 hours AZD5582 plus IFNγ significantly induced cell death, and apoptosis was detected by Annexin V Cancer Cell Int. 2018 Jun 14;18:84.
H1437 human NSCLC cell line 20 nM 60 hours AZD5582 plus IFNγ significantly induced cell death Cancer Cell Int. 2018 Jun 14;18:84.
A549 human NSCLC cell line 20 nM 72 hours AZD5582 alone had a minor effect on cell viability, but it could cooperate with IFNγ to induce cell death Cancer Cell Int. 2018 Jun 14;18:84.
Calu-3 human NSCLC cell line 20 nM 72 hours AZD5582 alone or plus IFNγ did not significantly affect cell viability Cancer Cell Int. 2018 Jun 14;18:84.
H441 human NSCLC cell line 20 nM 72 hours AZD5582 alone or plus IFNγ did not significantly affect cell viability Cancer Cell Int. 2018 Jun 14;18:84.
Primary normal human alveolar epithelial cells 20 nM 72 hours AZD5582 alone or plus IFNγ did not significantly affect cell viability Cancer Cell Int. 2018 Jun 14;18:84.
Hepa1-6 cells 25 µM AZD5582 synergistically with heat treatment significantly decreased the viability of Hepa1-6 cells, inhibited cell migration and proliferation, and induced apoptosis. Front Immunol. 2025 Jan 23;16:1482954.
Huh7 cells 25 µM AZD5582 synergistically with heat treatment significantly decreased the viability of Huh7 cells, inhibited cell migration and proliferation, and induced apoptosis. Front Immunol. 2025 Jan 23;16:1482954.
PANC-1 1.21 µM To evaluate the inhibitory effect of AZD5582 on the proliferation of pancreatic cancer cells Cancer Sci. 2024 Mar;115(3):820-835.
CFPAC-1 74.03 nM To evaluate the inhibitory effect of AZD5582 on the proliferation of pancreatic cancer cells Cancer Sci. 2024 Mar;115(3):820-835.
Total CD4+ T cells 100 nM 48 h Analyze the targeting effect of AZD5582 on the ncNF-κB pathway, results showed AZD5582 effectively degraded cIAP1 and activated p100/p52 Nature. 2020 Feb;578(7793):160-165.
Jurkat cells 10 pM to 1 μM 48 h Evaluate the induction of HIV transcription by AZD5582, results showed AZD5582 effectively induced HIV transcription Nature. 2020 Feb;578(7793):160-165.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rhesus macaques SIVmac239 infection model Intravenous injection 0.1 mg/kg Weekly for 5 weeks To evaluate the latency reversal effect of AZD5582 in ART-suppressed SIV-infected rhesus macaques Nat Med. 2023 Oct;29(10):2535-2546.
C57BL/6J mice and NTG mice Hepatocellular carcinoma xenograft model Intraperitoneal injection 0.3 mg/kg Once every 2 days for 12 days AZD5582 in combination with IMWA significantly inhibited the progression of hepatocellular carcinoma, induced apoptosis, and inhibited cell proliferation, while increasing the infiltration of CD8+ T cells and decreasing the infiltration of Foxp3+ regulatory T cells in the tumor microenvironment. Front Immunol. 2025 Jan 23;16:1482954.
BLT humanized mice HIV-1 infection model Intraperitoneal injection 3 mg/kg Single dose To evaluate the effect of AZD5582 on HIV latency reversal, results showed that AZD5582 induces HIV-RNA expression, particularly in multiple tissues. Nature. 2020 Feb;578(7793):160-165.
Mice PDX model Intravenous injection 3 mg/kg Once a week for 3 weeks To evaluate the inhibitory effect of AZD5582 on pancreatic cancer growth in the PDX model Cancer Sci. 2024 Mar;115(3):820-835.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.98mL

0.20mL

0.10mL

4.92mL

0.98mL

0.49mL

9.85mL

1.97mL

0.98mL

References

 

Historical Records

Categories